Otsuka Holdings Co Ltd
TSE:4578
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5 184
9 611
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Otsuka Holdings Co Ltd stock under the Base Case scenario is 9 509.75 JPY. Compared to the current market price of 8 613 JPY, Otsuka Holdings Co Ltd is Undervalued by 9%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Otsuka Holdings Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Otsuka Holdings Co Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Otsuka Holdings Co., Ltd. is a Japanese pharmaceutical and nutraceutical powerhouse, woven into the fabric of global health and wellness. Founded in 1964, the company has consistently focused on the discovery, development, and commercialization of innovative products aimed at tackling unaddressed medical needs. Otsuka's broad portfolio includes prescription drugs, particularly in the areas of psychiatry, neurology, and oncology, complemented by a robust range of consumer healthcare products such as drinks and nutritional supplements. With a commitment to research and development, the company invests significantly in innovative drug solutions, resulting in a legacy marked by breakthroughs suc...
Otsuka Holdings Co., Ltd. is a Japanese pharmaceutical and nutraceutical powerhouse, woven into the fabric of global health and wellness. Founded in 1964, the company has consistently focused on the discovery, development, and commercialization of innovative products aimed at tackling unaddressed medical needs. Otsuka's broad portfolio includes prescription drugs, particularly in the areas of psychiatry, neurology, and oncology, complemented by a robust range of consumer healthcare products such as drinks and nutritional supplements. With a commitment to research and development, the company invests significantly in innovative drug solutions, resulting in a legacy marked by breakthroughs such as Abilify, a treatment for schizophrenia and bipolar disorder, and an array of lifestyle products that support overall well-being.
For investors, Otsuka Holdings presents an intriguing blend of stability and growth potential. Its diversified business model mitigates dependence on any single market segment. The company’s strong financial foundation, supported by solid revenue from both its pharmaceutical and consumer health divisions, highlights its resilience even in challenging economic conditions. As Otsuka continues to expand its global footprint, particularly in emerging markets and through strategic partnerships, it positions itself to capitalize on the growing demand for innovative therapies and nutritional products. The company’s robust commitment to sustainability and social responsibility further enhances its attractiveness to investors looking for long-term value. With a vision centered on health, innovation, and quality of life, Otsuka stands as a formidable player in the healthcare landscape, poised for growth while delivering on its mission to create new products for a healthier world.
Otsuka Holdings Co., Ltd. is a diversified pharmaceutical and nutraceutical company based in Japan. The company operates through several core business segments:
-
Pharmaceuticals: This is one of the primary segments of Otsuka Holdings, focusing on the research, development, manufacture, and sale of pharmaceuticals. Otsuka is known for its innovative drugs, particularly in the areas of psychiatry and neurology, oncology, cardiovascular diseases, and infectious diseases.
-
Nutriceuticals: This segment includes the production and distribution of dietary supplements and functional foods. Otsuka is known for its products that promote health and wellness, including consumer healthcare products like beverages and nutritional foods.
-
Consumer Products: Within this segment, Otsuka develops and markets a variety of consumer products, including lifestyle and wellness products that aim to enhance health and quality of life.
-
International Operations: Otsuka has a significant focus on international markets. The company aims to expand its presence globally across its pharmaceutical and nutraceutical markets, leveraging partnerships and acquisitions to strengthen its international footprint.
-
Research and Development: Otsuka places a strong emphasis on R&D, investing significantly in innovation across its core segments to bring new and effective products to market. This includes both pharmaceutical and nutraceutical research aimed at developing advanced treatments and health solutions.
Otsuka's business model emphasizes innovation, quality, and a commitment to addressing unmet medical needs in the global healthcare market.
Otsuka Holdings Co., Ltd., a global healthcare company based in Japan, has several unique competitive advantages that distinguish it from its rivals:
-
Diverse Product Portfolio: Otsuka has a wide range of products across pharmaceuticals, nutraceuticals, and consumer products. This diversification helps mitigate risks associated with relying on a single product line and allows the company to capitalize on various market opportunities.
-
Strength in Research and Development: Otsuka invests significantly in R&D, focusing on innovative drug development, particularly in psychiatry, nephrology, and oncology. Its commitment to developing unique treatments, such as novel psychiatric medications, provides a strong competitive edge.
-
Global Expansion Strategy: Otsuka has strategically expanded its operations internationally, creating a strong global presence. This not only increases market reach but also allows the company to tap into diverse markets and benefit from localized strategies.
-
Acquisition Strategy: The company has a history of acquiring firms and technologies that complement its existing capabilities. This allows Otsuka to enhance its product pipeline, technology, and market positions more quickly than organic growth alone.
-
Strong Supply Chain and Manufacturing Capabilities: Otsuka’s efficient supply chain and manufacturing processes ensure quality production, cost-effectiveness, and scalability. This operational efficiency can lead to better margins compared to competitors who may face supply chain disruptions.
-
Commitment to Sustainability: Otsuka has integrated sustainability into its business model, appealing to socially conscious consumers and attracting potential partners and investors who value corporate social responsibility.
-
Strong Brand Reputation: With decades of experience and success in the healthcare sector, Otsuka has built a strong brand reputation, instilling trust among healthcare professionals and consumers.
-
Focus on Niche Markets: Otsuka targets niche markets, particularly those that are under-served, such as mental health. This positioning allows the company to escape intense price competition often seen in more generic markets.
-
Collaborative Approach: Otsuka often collaborates with academic institutions, healthcare professionals, and other companies to facilitate research and development. These partnerships can enhance innovation and expedite the drug development process.
-
Patient-Centric Approach: The company’s emphasis on understanding patient needs and developing solutions tailored to those needs fosters loyalty among healthcare providers and patients alike, creating a competitive advantage in customer relationships.
By leveraging these unique strengths, Otsuka Holdings positions itself advantageously in the highly competitive pharmaceutical and healthcare sectors.
Otsuka Holdings Co., Ltd., a Japan-based pharmaceutical and nutraceutical company, faces several risks and challenges in the near future. While specific risks may evolve over time, the following key areas are likely to be significant:
-
Regulatory Challenges: The pharmaceutical industry is heavily regulated. Changes in regulations or compliance issues can affect drug approvals, market access, and operational costs.
-
Patent Expiration: As with many pharmaceutical companies, the expiration of patents for key drugs can lead to generic competition, significantly impacting revenue.
-
R&D Risks: The pharmaceutical industry relies heavily on research and development. High rates of failure in clinical trials can lead to substantial financial loss, and the high costs of R&D may not always translate into successful products.
-
Competition: Intense competition from both established pharmaceutical companies and new entrants, especially in therapeutic areas like mental health and oncology, could pressure market share and pricing.
-
Global Supply Chain Disruptions: Global events (e.g., pandemics, geopolitical tensions) can disrupt supply chains, affecting production and distribution of pharmaceuticals, particularly for critical products.
-
Market Access and Reimbursement Pressures: In various markets, including the U.S. and Europe, payers are increasingly scrutinizing drug pricing and value propositions, which may limit access to products.
-
Changing Consumer Preferences: Growing interest in personalized medicine and biotechnology may require Otsuka to adapt its strategy to remain competitive.
-
Economic Conditions: Fluctuating economic conditions, including inflation and healthcare budgets, can impact consumer spending on health-related products and services.
-
Technological Advancements: Rapid advancements in technology could lead to disruption within the industry, requiring Otsuka to invest heavily in innovation to keep pace.
-
Reputational Risks: Issues around product safety, efficacy, or ethical marketing practices can lead to reputational damage, affecting customer trust and sales.
-
International Operations and Currency Fluctuations: Operating in various countries exposes Otsuka to currency risk and geopolitical instability, which can impact overall performance.
Managing these risks effectively is crucial for Otsuka Holdings to sustain its competitive advantage and ensure long-term growth. Conducting thorough risk assessments and developing strategic responses will be essential in navigating these challenges.
Revenue & Expenses Breakdown
Otsuka Holdings Co Ltd
Balance Sheet Decomposition
Otsuka Holdings Co Ltd
Current Assets | 1.4T |
Cash & Short-Term Investments | 606.3B |
Receivables | 475.5B |
Other Current Assets | 353.1B |
Non-Current Assets | 2.2T |
Long-Term Investments | 503.5B |
PP&E | 578.8B |
Intangibles | 901B |
Other Non-Current Assets | 179.6B |
Current Liabilities | 747B |
Accounts Payable | 182.8B |
Other Current Liabilities | 564.3B |
Non-Current Liabilities | 342.6B |
Long-Term Debt | 147.8B |
Other Non-Current Liabilities | 194.8B |
Earnings Waterfall
Otsuka Holdings Co Ltd
Revenue
|
2.3T
JPY
|
Cost of Revenue
|
-648.6B
JPY
|
Gross Profit
|
1.6T
JPY
|
Operating Expenses
|
-1.2T
JPY
|
Operating Income
|
400.1B
JPY
|
Other Expenses
|
-248.5B
JPY
|
Net Income
|
151.6B
JPY
|
Free Cash Flow Analysis
Otsuka Holdings Co Ltd
JPY | |
Free Cash Flow | JPY |
In the second quarter of FY 2024, the company saw significant growth with revenue increasing 17% to JPY 1,109.8 billion and business profit up 37.8% to JPY 213.6 billion. Strong performance in pharmaceutical and nutraceutical businesses fueled this growth. The revenue forecast for FY 2024 has been revised upward by JPY 175 billion to JPY 2,315 billion, and business profit is now projected to be JPY 390 billion. Notably, net profit is expected to double compared to 2023, reaching JPY 240 billion. The company also announced a JPY 50 billion share repurchase plan for FY 2024.
What is Earnings Call?
Profitability Score
Profitability Due Diligence
Otsuka Holdings Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Otsuka Holdings Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Otsuka Holdings Co Ltd's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Score
Otsuka Holdings Co Ltd's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Otsuka Holdings Co Ltd
According to Wall Street analysts, the average 1-year price target for Otsuka Holdings Co Ltd is 9 008.45 JPY with a low forecast of 6 161 JPY and a high forecast of 11 340 JPY.
Dividends
Current shareholder yield for Otsuka Holdings Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Otsuka Holdings Co., Ltd. engages in the manufacture and sale of pharmaceuticals and nutritional supplements. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 33,226 full-time employees. The company went IPO on 2010-12-15. The firm operates through four business segments. The Medical-related segment is engaged in the sale of ethical drugs, and the research development and export of therapeutic drugs. The Nutraceuticals-related segment is engaged in the manufacture, purchase and sale of nutraceuticals-related products, such as functional food and dietary supplements. The Consumer-related segment is engaged in the manufacture and sale of consumer products and mineral water. The Others segment is engaged in the manufacture and sale of chemical products, the manufacture, sale and import of measuring equipment, and the manufacture of synthetic resin molding products.
Contact
IPO
Employees
Officers
The intrinsic value of one Otsuka Holdings Co Ltd stock under the Base Case scenario is 9 509.75 JPY.
Compared to the current market price of 8 613 JPY, Otsuka Holdings Co Ltd is Undervalued by 9%.